Finnegan expanded its London team with the addition of Jin Ooi as a partner. Jin joined the firm on June 8, bringing over 15 years of patent litigation experience with an emphasis in the pharmaceutical, biotech, and medical devices industries.
Jin has been involved in significant patent litigation matters, including disputes relating to pharmaceutical products such as pregabalin and enzalutamide, as well as cases involving interim injunctions for treatments like empagliflozin.
In addition to life sciences litigation, Jin has experience in standard-essential patent disputes and FRAND-related matters. He has acted for clients in the electronics space, and has worked on disputes in the consumer goods sector, including litigation between major tobacco companies.
His practice also includes trade secrets arbitration and commercial and regulatory disputes, along with transactional support for mergers and acquisitions in regulated industries.
According to Darren Jiron, managing partner of Finnegan’s London office, Jin’s arrival reflects the growing client demand for coordinated litigation strategies across the UK, U.S., and Europe. At Finnegan, Jin will support the firm’s ability to handle global disputes, particularly in life sciences and FRAND matters, as part of its continued expansion in Europe.
Read “Finnegan Hires Kirkland & Ellis Litigator for London Office”
Commentary
Patent Strategy Could Shape Financing, Valuation and Risk in Offshore Energy Projects
June 30, 2026
Award/Ranking
Finnegan’s European Practices and Attorneys Highlighted in 2026 Managing IP Rankings
June 25, 2026
Award/Ranking
Six Finnegan Partners Recognized in the 2026 Lawdragon 500 Leading Global IP Lawyers
June 22, 2026
Award/Ranking
World Trademark Review Recognizes Three Finnegan Partners on its 2026 Global Leaders List
June 24, 2026
Press Release
London-Based Life Sciences Litigator Jin Ooi Bolsters Finnegan’s Global IP Litigation Capabilities
June 8, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.